Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating IMVT-1402, a drug being studied for adults with Graves disease GD who remain hyperthyroid despite antithyroid drug treatment. This Phase 2b, randomized, double-blind, placebo-controlled study aims to assess the drugs efficacy, safety, and tolerability in a global, multi-center setting. Participants are assigned to receive one of two doses of IMVT-1402 or a placebo for 26 weeks. The study compares these groups to see how well IMVT-1402 helps participants become euthyroid normal thyroid function and stop antithyroid drugs. The two doses are given over the same 26-week period, with monitoring at several time points. During the trial, participants will undergo regular evaluations including thyroid hormone measurements such as triiodothyronine T3 and free thyroxine FT4. Researchers will measure how many participants achieve normal thyroid hormone levels and are off antithyroid drugs by Week 26. Safety and tolerability are also monitored throughout. The main outcome is the percentage of participants who are euthyroid and off antithyroid drugs at Week 26, with follow-up assessments planned for this duration.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
Actively Recruiting
This research aims to evaluate the effectiveness of closed-loop spinal cord stimulation CL-SCS therapy in patients suffering from painful chemotherapy induced peripheral neuropathy CIPN. CIPN affects up to 40% of chemotherapy patients and causes significant pain. Traditional treatments include medications and other interventions, but evidence for their success is limited. CL-SCS is an advanced method that stimulates nerves in the spinal cord and adjusts stimulation automatically in real time to manage pain. The study involves patients diagnosed with painful CIPN who are scheduled for CL-SCS implantation using the Evoke SCS System. This system sends electrical pulses to the spinal cord, measures nerve responses, and adapts stimulation accordingly. The research observes patients receiving this treatment without a comparison group, tracking effects over time. Participants will be followed for up to 12 months after implantation. Researchers will assess changes in overall pain intensity, pain in arms or legs, CIPN symptoms, medication use, quality of life, and patient satisfaction at 1, 3, 6, and 12 months. Safety will be monitored by recording any serious adverse events during this period. The study collects detailed patient reports and device data to understand CL-SCS therapys impact on pain and quality of life in CIPN patients.
Actively Recruiting
Researchers are evaluating how lower doses of oral semaglutide can help reduce body weight in adults with excess body weight, including those with overweight or obesity. The study aims to identify the best lower dose of oral semaglutide for treating weight management. This is a phase 3 clinical trial sponsored by Novo Nordisk AS. Participants will be randomly assigned to receive one of two oral doses of semaglutide or a placebo, all combined with a reduced-calorie diet and increased physical activity. The treatment lasts for 60 weeks, during which participants take the study medication daily. The study compares the effects of these doses on body weight and related health measures. Throughout the 60-week study, participants will be monitored for changes in body weight, waist circumference, blood pressure, blood glucose, cholesterol levels, and inflammation markers. Researchers will assess weight loss success at several thresholds 5%, 10%, 15% and track any adverse events up to week 67. Regular visits will include physical assessments and laboratory tests to evaluate safety and effectiveness over the study period.